In a move to help underserved women join the workforce and to strengthen the impact of its employee volunteer efforts, The Bloc joined the business community of Working for Women (W4W).
Roche culled two more Phase II Covid-19 programs, as announced in the Swiss pharma giant’s first-quarter 2021 financial report.
Johnson & Johnson is establishing a vaccine supply network in which 10 manufacturing sites would be involved in the production of the company’s Covid-19 vaccine, in addition to J&J’s plant in Leiden, the Netherlands.
The U.S. Food and Drug Administration requested that Emergent BioSolutions temporarily pause production of ingredients for the Johnson & Johnson Covid-19 vaccine at their facility in Baltimore.
The tenth annual Pharmaceutical Innovation Index, released April 21, sees Eli Lilly top the industry for the first time. The Pharmaceutical Invention Index, a ranking of the industry’s best pipelines, rated Bristol Myers Squibb as No. 1.
Swiss drugmaker Roche predicted on April 21 that demand for the company’s drugs would accelerate for the remainder of 2021, after first-quarter sales of Covid-19 tests offset a pandemic-influenced slump in its main pharmaceuticals business.
Japan’s government is considering a state of emergency for Tokyo and Osaka as new Covid-19 case numbers surge, broadcaster NHK reported on Wednesday, a move that would enable prefectural authorities to impose curbs to try to stop infections spreading.
Johnson & Johnson said on April 20 the company will resume rolling out its Covid-19 vaccine in Europe after the region’s medical regulator said the benefits of the shot outweigh the risk of very rare, potentially lethal blood clots.
One month after acquiring Five Prime Therapeutics and the company’s Phase III ready anti-FGFR2b antibody bemarituzumab for $1.9 billion, Amgen announced that the U.S. Food and Drug Administration awarded Breakthrough Therapy Designation to the asset as a first-line treatment for certain types of gastric cancer.
The U.S. Food and Drug Administration placed a clinical hold on KalVista Pharmaceuticals’ proposed Phase II trial of KVD824, a prophylactic treatment of hereditary angioedema. The regulatory agency requested additional information and analysis of preclinical studies regarding KVD824 before giving the go-ahead to the Phase II trial.
